Norleucine

Norleucine

SCHEMBL7430731

CCCC[C@H](N)C(=O)O.O=C(O)CCN[C@H](CCc1ccccc1)C(=O)O

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 3/20 0.48
GGT1 P19440 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
S1PR2 O95136 2/20 0.45
S1PR1 P21453 2/20 0.45
S1PR3 Q99500 1/20 0.45
CTSK P43235 1/20 0.43
GRIK1 P39086 1/20 0.42
HPGD P15428 1/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA4 P43681 1/20 0.42
HDAC3 O15379 1/20 0.41
LTA4H P09960 1/20 0.41
TLR2 O60603 1/20 0.41
MME P08473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7382823 0.95 NOD1 (0.52) NOD1GGT1CYP1A2CYP2C9CYP2C19
SCHEMBL7383218 0.92 GGT1 (0.53) GGT1GRIK1HDAC3LTA4HMME
Homophenylalanine SCHEMBL7383933 0.90 GGT1 (0.50) GGT1GRIK1HDAC3LTA4HMME
Ornithine SCHEMBL7376158 0.89 GGT1 (0.48) GGT1GRIK1CHRNB2CHRNB4CHRNA3
Glutamic Acid SCHEMBL7375280 0.89 GGT1 (0.49) GGT1CYP1A2GRIK1LTA4HMME
Lysine SCHEMBL7384968 0.88 GGT1 (0.47) GGT1GRIK1CHRNB2CHRNB4CHRNA3
Serine SCHEMBL7384366 0.85 GGT1 (0.48) GGT1GRIK1HDAC3LTA4HMME
Phenylalanine SCHEMBL7432097 0.85 ALPI (0.56) GGT1LTA4HMME
Alanine SCHEMBL7382718 0.85 GGT1 (0.50) GGT1CYP2C9CYP2C19HPGDMME
SCHEMBL6423726 0.85 GGT1 (0.57) GGT1HDAC3MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP disclosed
EP-1063991-A1 STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS WARNER-LAMBERT COMPANY LLC (US) 2001-01-03 EP disclosed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO disclosed
WO-1999047138-A1 STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS WARNER-LAMBERT COMPANY (US) 1999-09-23 WO disclosed